title: A novel, species-specific class of uncompetitive inhibitors of gamma-glutamyl transpeptidase.
abstract: Expression of gamma-glutamyl transpeptidase (GGT) in tumors contributes to resistance to radiation and chemotherapy. GGT is inhibited by glutamine analogues that compete with the substrate for the gamma-glutamyl binding site. However, the glutamine analogues that have been evaluated in clinical trials are too toxic for use in humans. We have used high throughput screening to evaluate small molecules for their ability to inhibit GGT and have identified a novel class of inhibitors that are not glutamine analogues. These compounds are uncompetitive inhibitors, binding the gamma-glutamyl enzyme complex. OU749, the lead compound, has an intrinsic K(i) of 17.6 microm. It is a competitive inhibitor of the acceptor glycyl-glycine, which indicates that OU749 occupies the acceptor site while binding to the gamma-glutamyl substrate complex. OU749 is more than 150-fold less toxic than the GGT inhibitor acivicin toward dividing cells. Inhibition of GGT by OU749 is species-specific, inhibiting GGT isolated from human kidney with 7-10-fold greater potency than GGT isolated from rat or mouse kidney. OU749 does not inhibit GGT from pig cells. Human GGT expressed in mouse fibroblasts is inhibited by OU749 similarly to GGT from human cells, which indicates that the species specificity is determined by differences in the primary structure of the protein rather than species-specific, post-translational modifications. These studies have identified a novel class of inhibitors of GGT, providing the basis for further development of a new group of therapeutics that inhibit GGT by a mechanism distinct from the toxic glutamine analogues.
authors.affiliation: Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
authors.forename: Jarrod B
authors.initials: JB
authors.lastname: King
authors.forename: Matthew B
authors.initials: MB
authors.lastname: West
authors.forename: Paul F
authors.initials: PF
authors.lastname: Cook
authors.forename: Marie H
authors.initials: MH
authors.lastname: Hanigan
mesh_terms: D000818:Animals; D002460:Cell Line; D020650:Combinatorial Chemistry Techniques; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000145:classification / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D000882:Haplorhini; D007700:Kinetics; D015394:Molecular Structure; D051381:Rats; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000145:classification / Q000494:pharmacology*; D013552:Swine; D013830:Thiadiazoles / Q000138:chemical synthesis* / Q000145:classification / Q000494:pharmacology*; D005723:gamma-Glutamyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000096926:Benzenesulfonamides
chemical_list: D004791:Enzyme Inhibitors; D005978:Glutathione; D013449:Sulfonamides; D013830:Thiadiazoles; D005723:gamma-Glutamyltransferase; C540802:N-(5-(4-methoxybenzyl)-1,3,4-thiadiazol-2-yl)benzenesulfonamide; D000096926:Benzenesulfonamides